A Validation of the 64-Gene Signature Using Affymetrix-HG_U133A Array in Stage I NSCLC From the CALGB Lung Cancer Study (140202)
- Determine whether the 64-gene signature can accurately predict the prognosis for
survival of patients with stage I non-small cell lung cancer (NSCLC).
OUTLINE: RNA is purified from tissue samples obtained by the CALGB Lung Cancer Study
(CALGB-140202). The RNA samples are used for gene expression analysis using the 64-gene
signature and an Affymetrix-HG_U133A array. Reverse-transcriptase PCR may also be performed
on selected samples.
Overall survival, defined as the time from surgery to death of any cause
Ming You, MD
Washington University Siteman Cancer Center
United States: Federal Government